FDA Approval of Icotyde Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis With a Targeted Oral Peptide
March 19, 2026
March 19, 2026
RARITAN, New Jersey, March 19 -- Johnson and Johnson Innovative Medicine issued the following news release on March 18, 2026:
* * *
FDA approval of ICOTYDE(TM) (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill
ICOT . . .
* * *
FDA approval of ICOTYDE(TM) (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill
ICOT . . .